A similar trend was also observed in PANC1 models, where the EPLIN knockdown group resulted in lower IC50s to these two key therapeutic agents for pancreatic cancer compared to the control group (Fig. 6D&E and Table 3). This evidence concerns the gene LIMA1 and pancreatic neoplasm.